Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DesiReS: Rituximab in Systemic Sclerosis
NCT04274257Phase 3Completed
- Sponsor
- The University of Tokyo
- Start
- Dec 2017
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in systemic sclerosis (SSc), sponsored by The University of Tokyo. Started Dec 2017; status: completed.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04274257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274257.